Clínica Universidad de Navarra (CUN)
Centro clínico de la Universidad de Navarra
University of Alberta
Edmonton, CanadáPublicacions en col·laboració amb investigadors/es de University of Alberta (36)
2024
-
Revised European Association for Palliative Care (EAPC) recommended framework on palliative sedation: An international Delphi study
Palliative Medicine, Vol. 38, Núm. 2, pp. 213-228
2022
-
Clinical, histological and molecular profiling of different stages of alcohol-related liver disease
Gut, Vol. 71, Núm. 9, pp. 1856-1866
-
Consensus Statement on Bone Conduction Devices and Active Middle Ear Implants in Conductive and Mixed Hearing Loss
Otology and Neurotology, Vol. 43, Núm. 5, pp. 513-529
-
Correction to: The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study
The American journal of gastroenterology, Vol. 117, Núm. 5, pp. 818
-
Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement
Obesity Facts, Vol. 15, Núm. 3, pp. 321-335
-
Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement
Clinical Nutrition, Vol. 41, Núm. 4, pp. 990-1000
-
Impact of muscle mass on survival of patients with hepatocellular carcinoma after liver transplantation beyond the Milan criteria
Journal of Cachexia, Sarcopenia and Muscle, Vol. 13, Núm. 5, pp. 2373-2382
-
The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study
American Journal of Gastroenterology, Vol. 117, Núm. 2, pp. 301-310
2021
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
2020
-
Critical appraisal of definitions and diagnostic criteria for sarcopenic obesity based on a systematic review
Clinical Nutrition, Vol. 39, Núm. 8, pp. 2368-2388
-
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
Blood Cancer Journal, Vol. 10, Núm. 9
2019
-
Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide
Clinical Gastroenterology and Hepatology, Vol. 17, Núm. 11, pp. 2320-2329.e12
-
Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
Nature Communications, Vol. 10, Núm. 1
-
Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition
JCO Precision Oncology
2018
-
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of POLLUX
Haematologica, Vol. 103, Núm. 12, pp. 2088-2096
-
Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis
Journal of Hepatology, Vol. 69, Núm. 2, pp. 396-405
-
Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment
Diabetes, Obesity and Metabolism, Vol. 20, Núm. 12, pp. 2860-2868
-
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial
The Lancet Oncology, Vol. 19, Núm. 11, pp. 1530-1542
-
Treatable inherited rare movement disorders
Movement Disorders, Vol. 33, Núm. 1, pp. 21-35
2017
-
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth
British Journal of Haematology, Vol. 178, Núm. 6, pp. 896-905